New research indicates that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a prominent health publication points out that while overweight individuals often shed substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users purchasing such treatments need to be informed of the risk of rapid weight regain when the treatment is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to pre-treatment weight within about 18 months.
Comparing Treatments
The research, which examined dozens of trials involving thousands of patients, contrasted the effects of the injectable medications with other pills.
Scientists emphasize that people who lose weight through dieting typically experience a more gradual creep back—approximately 0.1 kg a month—after stopping.
Explaining the Quick Regain
Nutrition scientists propose the mechanism of the jabs accounts for the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to generate a reduced amount of its endogenous GLP-1, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in appetite is no longer kept in check, making excessive eating far more likely."
An Ongoing Condition?
The NHS recommend the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the likelihood of relapse, the therapy should be considered ongoing.
This view is echoed by pharmaceutical companies, who note that the results "underscore the persistent character of excess weight," similar to managing conditions like hypertension.
Patient Experiences
People who have stopped the medication explain a intense return of cravings.
"I experienced something activating and I was suddenly ravenous," said one woman.
The struggle is compounded if patients have not developed sustainable dietary or behavioural modifications during treatment.
Significant Use
Survey data indicate that millions of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is higher among females compared to men.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent solution and maintained weight loss hinges on integrated behavioural support.
